M
Mark W Weatherall
Researcher at Stoke Mandeville Hospital
Publications - 3
Citations - 10
Mark W Weatherall is an academic researcher from Stoke Mandeville Hospital. The author has contributed to research in topics: Calcitonin gene-related peptide & Autoinjector. The author has an hindex of 2, co-authored 3 publications receiving 8 citations.
Papers
More filters
Journal ArticleDOI
Headache: an important symptom possibly linked to white matter lesions in thalassaemia
Anuja Premawardhena,Udaya K. Ranawaka,Taraka Pilapitiya,Gihan Weerasinghe,A. Hapangama,Shantha Hettiarachchi,Arunasalam Pathmeswaran,K.A. Salvin,Ishari Silva,Nizri Hameed,Mark W Weatherall,Nancy F. Olivieri,David J. Weatherall +12 more
TL;DR: It is found that headaches were more common in thalassaemia patients than in controls and WMCs were not associated with reduction of cognition, but cognition was lower in the TI and EBT groups compared with those with TM.
Journal ArticleDOI
Percutaneous electrical nerve stimulation (PENS) therapy for refractory primary headache disorders: a pilot study.
Mark W Weatherall,Dipankar Nandi +1 more
TL;DR: PENS therapy shows potential as a relatively non-invasive, low-risk, and inexpensive component of the treatment options for refractory primary headache disorders, particularly CCH.
Journal ArticleDOI
Fremanezumab autoinjector pen for the prevention of migraine.
TL;DR: Ajovy (fremanezumab, Teva Pharmaceuticals, Israel) is a fully humanized monoclonal antibody that selectively binds both isoforms of the calcitonin gene-related peptide as mentioned in this paper.